Testing Needed for Acesulfame Potassium, an Artificial Sweetener

Potassium, an Artificial Sweetener In their article “First Experimental Demonstration of the Multipotential Carcinogenic Effects of Aspartame Administered in the Feed of Sprague-Dawley Rats,” Soffritti et al. (2006) present interesting data on the carcinogenic effects of longterm exposure to aspartame, an artificial sweetener, in experimental animals (rats). Recently, aspartame was supplanted as the leading artificial sweetener by sucralose, marketed in the United States under the trade name Splenda (McNeil Nutritionals, LLC, Ft. Washington, PA). As of 2005, Splenda was reported to have > 50% of the market for artificial sweeteners, while aspartame [Equal (Merisant Company, Chicago, IL); NutraSweet (NutraSweet Property Holdings Inc., Chicago, IL)] had < 20% (Associated Press 2005). Splenda is typically used in sweetener blends, most frequently with acesulfame potassium (CAS RN 55589-62-3) (Sunett; marketed in the United States by Nutrinova, Somerset, NJ). The Food and Drug Administration’s (FDA) multiple approvals of food additive petitions (FAPs) for acesulfame began in 1988 (FDA 1988), and culminated in 1998 with approval of the use of acesulfame in soft drinks (FDA 1998), historically the largest single use of artificial sweeteners. All of the FDA’s approvals of FAPs for acesulfame were grounded on the conclusion that safety studies, including long-term animal tests of acesulfame carried out for Hoechst, the manufacturer of the chemical, in the Netherlands in the 1970s, were adequate and the test results indicated safety. The 1970s tests of acesulfame—two tests carried out in rats and one in mice— are inadequate to establish lack of potential carcinogenicity. Here are a few reasons why the tests are inadequate [Center for Science in the Public Interest (CSPI) 1996]: • Subchronic tests were not conducted for the rats and mice used in the tests on which the FAPs rested • It is likely the minimum toxic dose/maximum tolerated dose (MTD) was not achieved in the rat and mouse studies • Randomization of test groups was not carried out properly • Mice were held on test for only 80 weeks, rather than the 104 weeks characteristic of National Toxicology Program (NTP) bioassays • Animal husbandry and monitoring of animals on test were evidently poor, as indicated by high disease rates in the animals and extensive autolysis of tissues. Even with the flaws in design and execution of the Hoechst tests, results indicated an association between treatment with acesulfame and carcinogenesis (CSPI 1996). Working-level staff members at the FDA identified deficiencies in the acesulfame tests in the 1980s (McLaughlin 1986; Taylor 1986). Thus, an FDA staff member (Taylor 1986) noted in 1986, when the FDA had decided to accept the Hoechst studies, that The question remains whether these studies are sufficiently definitive or rigorous in light of the potential for widespread, [sic] high exposure to acesulfame K in all group [sic] in the population.